95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Xiaolin Zhang1†Minghui Cheng1†Naijing Gao1†
Yi Li1Chenghui Yan1
Xiaoxiang Tian1Dan Liu1
Miaohan Qiu1Xiaozeng Wang1Bo Luan2Jie Deng3Shouli Wang4Hongyan Tian5Geng Wang1Xinliang Ma6Gregg W. Stone7
Yaling Han1*- 1Cardiovascular Research Institute and Department of Cardiology, The General Hospital of Northern Theater Command, Shenyang, China
- 2Department of Cardiology, Liaoning Provincial People's Hospital, Shenyang, China
- 3Department of Cardiology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- 4Department of Cardiology, General Hospital of the Strategic Support Force of the Chinese People's Liberation Army, Beijing, China
- 5Department of Cardiology First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
- 6Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States
- 7Icahn School of Medicine at Mount Sinai, Mount Sinai Heart and the Cardiovascular Research Foundation, New York, NY, United States
A Corrigendum on
Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction
by Zhang, X., Cheng, M., Gao, N., Li, Y., Yan, C., Tian, X., Liu, D., Qiu, M., Wang, X., Luan, B., Deng, J., Wang, S., Tian, H., Wang, G., Ma, X., Stone, G. W., and Han, Y. (2021). Front. Cardiovasc. Med. 8:747511. doi: 10.3389/fcvm.2021.747511
In the original article, the Funding statement is incorrect. The authors neglected to include the funder “National Key Research and Development Program of China, 2016YFC1301303” for author YH and the funder “Liaoning Provincial Natural Science Foundation of China, 2019-ZD-1060” for author XZ. The corrected Funding statement appears below:
“This work was supported by grants from the National Key Research and Development project of China [grant number 2016YFC1301300]. YH received funding from the National Key Research and Development Program of China, 2016YFC1301303. XZ received funding from the Liaoning Provincial Natural Science Foundation of China, 2019-ZD-1060. The funders of the study had no role in study design, data collection, analysis, interpretation, or writing of the report. The authors had access to the data and vouch for the integrity, accuracy, and completeness of the data and analyses, and for the fidelity of the study to the protocol.”
In the original article, an error was made in the Abstract, section Design, Setting, and Participants. The original sentence was incorrectly written as: “An independent cohort of 398 patients enrolled at three different hospitals served as a validation cohort.” The correct sentence is: “An independent cohort of 243 patients enrolled at three different hospitals served as a validation cohort.”
In the original article, an error was made in the Methods, section Study Design and Participants. The original sentence was incorrectly written as: “A second patient group, serving as a validation cohort, comprised 398 patients with the same inclusion and exclusion criteria presenting to the emergency department of three different hospitals (eAppendix 1) between May 2016, and November 2016”. The correct sentence is: “A second patient group, serving as a validation cohort, comprised 243 patients with the same inclusion and exclusion criteria presenting to the emergency department of three different hospitals (eAppendix 1) between May 2016 and November 2016.”
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: S100A12, ST-segment elevation myocardial infarction, diagnosis, prognosis, cardiovascular disease(s)
Citation: Zhang X, Cheng M, Gao N, Li Y, Yan C, Tian X, Liu D, Qiu M, Wang X, Luan B, Deng J, Wang S, Tian H, Wang G, Ma X, Stone GW and Han Y (2022) Corrigendum: Utility of S100A12 as an Early Biomarker in Patients With ST-Segment Elevation Myocardial Infarction. Front. Cardiovasc. Med. 9:840102. doi: 10.3389/fcvm.2022.840102
Received: 20 December 2021; Accepted: 02 February 2022;
Published: 23 February 2022.
Edited and reviewed by: Tommaso Gori, Johannes Gutenberg University Mainz, Germany
Copyright © 2022 Zhang, Cheng, Gao, Li, Yan, Tian, Liu, Qiu, Wang, Luan, Deng, Wang, Tian, Wang, Ma, Stone and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yaling Han, aGFueWFsaW5nQDE2My5uZXQ=
†These authors have contributed equally to this work and share first authorship